Document is current
Any future updates will be listed below
-
Authors
Ackmann, Jana
Brüge, Alina
Gotina, Lizaveta
Lim, Sungsu
Jahreis, Kathrin
Vollbrecht, Anna-Lena
Kim, Yun Kyung
Pae, Ae Nim
Labus, Josephine
Ponimaskin, Evgeni
-
Funding
Funding for this research was provided by:
Hannover Biomedical Research School - Graduate School of Excellence (StrucMed-Scholarship)
Hannover Biomedical Research School - Graduate School of Excellence (StrucMed-Scholarship)
Hannover Biomedical Research School - Graduate School of Excellence (StrucMed-Scholarship)
Korea Institute of Science and Technology Information (KSC-2022-CRE-0435)
Korea Institute of Science and Technology Information (KSC-2022-CRE-0435)
Korea Institute Science and Technology (KIST) institutional Program (2E32161)
Korea Institute Science and Technology (KIST) institutional Program (2E32161)
Deutsche Forschungsgemeinschaft (LA4465)
Deutsche Forschungsgemeinschaft (PO732)
Medizinische Hochschule Hannover (MHH)
- License Information
-
More Information
Article History
Received: 7 December 2023
Accepted: 11 April 2024
First Online: 19 April 2024
Declarations
:
: Not applicable.
: Not applicable.
: Josephine Labus and Evgeni Ponimaskin are co-inventors in the international patent WO2020/065090 describing the targeting of 5-HT7 receptor for treatment of tauopathies. All other authors declare that they have no conflicts of interest with the contents of this article.
